Status:
COMPLETED
Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Neoplasms, Breast
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a safety and tolerability study of GW572016 given with docetaxel (TAXOTERE).
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Advanced solid tumors.
- Able to swallow oral medication.
Exclusion
Key Trial Info
Start Date :
April 28 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 21 2006
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00148902
Start Date
April 28 2003
End Date
January 21 2006
Last Update
December 6 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Detroit, Michigan, United States, 48201
2
GSK Investigational Site
Nashville, Tennessee, United States, 37203